公开(公告)号：EP2254998A1

公开(公告)日：2010-12-01

申请号：EP09713841.6

申请日：2009-02-27

申请人： Argos Therapeutics, Inc. ,  The Board of Trustees of The Leland Stanford Junior University

发明人： NICOLETTE, Charles ,  FATHMAN, C., Garrison ,  CREUSOT, Remi

IPC分类号： C12N15/00

CPC分类号： C12N15/86 ,  A61K38/2026 ,  A61K48/00 ,  A61K48/005 ,  A61K2035/124 ,  C12N5/0639 ,  C12N2501/23 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2510/00 ,  C12N2740/15043

摘要： A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-gamma receptor antagonist, an IFN-alpha receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions.

公开(公告)号：EP2254998B1

公开(公告)日：2015-12-23

申请号：EP09713841.6

申请日：2009-02-27

申请人： Argos Therapeutics, Inc. ,  The Board of Trustees of the Leland Stanford Junior University

发明人： NICOLETTE, Charles ,  FATHMAN, C., Garrison ,  CREUSOT, Remi

IPC分类号： C12N15/00

CPC分类号： C12N15/86 ,  A61K38/2026 ,  A61K48/00 ,  A61K48/005 ,  A61K2035/124 ,  C12N5/0639 ,  C12N2501/23 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2510/00 ,  C12N2740/15043

摘要： A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-gamma receptor antagonist, an IFN-alpha receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions.

公开(公告)号：EP0627934A1

公开(公告)日：1994-12-14

申请号：EP93907049.0

申请日：1993-02-25

申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ,  IMMULOGIC PHARMACEUTICAL CORPORATION

发明人： FATHMAN, C., Garrison ,  PABORSKY, Lisa ,  GELBER, Cohava

IPC分类号： G01N33 ,  A61K39 ,  A61P37 ,  C07K14 ,  C07K16 ,  C12N1 ,  C12N5 ,  C12N15 ,  C12P21 ,  A61K38

CPC分类号： C07K14/705 ,  A61K38/00 ,  G01N33/5091

摘要： L'invention se rapporte à des antigènes associés à des cellules ilôts beta qui activent les populations de lymphocytes T en induisant le diabète de type I. Ces antigènes peuvent être utilisés dans le diagnostic et la thérapie du diabète de type I.